Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:29 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1057–1080 of 4,175 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control comparison Clear all

Conditions: Pain, Postoperative, Major Abdominal Surgery
Interventions: TAP block, Epidural analgesia, EXPAREL, Bupivacaine; Procedure · Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 85 Years
Enrollment: 514 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 2
States / cities: Cleveland, Ohio

Conditions: Axial Spondyloarthritis
Interventions: Brodalumab 210 mg, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 3
States / cities: Scottsdale, Arizona • Oklahoma City, Oklahoma • Duncansville, Pennsylvania

Conditions: Diabetic Peripheral Neuropathy
Interventions: Tapentadol extended release (ER), Placebo; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years and older
Enrollment: 460 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 60
States / cities: Mobile, Alabama • Chandler, Arizona • Mesa, Arizona + 57 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Cagrilintide, Semaglutide, Placebo cagrilintide, Placebo semaglutide; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 2,734 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 100
States / cities: Birmingham, Alabama • Pelham, Alabama • Phoenix, Arizona + 79 more

Conditions: Diabetes Mellitus
Interventions: Exantide with Dapagliflozin, Exentide, Dapagliflozin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 695 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 76
States / cities: Birmingham, Alabama • Huntsville, Alabama • Tuscumbia, Alabama + 61 more

Conditions: Spinal Cord Injuries
Interventions: Activity-Based Locomotor Exercise Program (ABLE); Behavioral
Lead sponsor: Allina Health System; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Golden Valley, Minnesota

Conditions: GIST
Interventions: EUS-TCB needle (QuickCore) standard of care, EUS-Guided biopsy needle (ProCore); Device
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Kidney Diseases
Interventions: Not listed
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 18 Years to 75 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2011
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Coagulopathy
Interventions: Resusix, FP24 (Frozen Plasma); Biological
Lead sponsor: Entegrion, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 3
States / cities: Tucson, Arizona • St Louis, Missouri • Charlotte, North Carolina

Conditions: Geographic Atrophy
Interventions: JNJ-81201887, Prednisone, Placebo, Triamcinolone, Sham Procedure; Drug · Other
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 60 Years and older
Enrollment: 305 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 79
States / cities: Phoenix, Arizona • Tucson, Arizona • Fullerton, California + 66 more

Conditions: Hospitalized Neonates and Infants, Expected to Require Parenteral Nutrition for 28 Days
Interventions: Smoflipid 20% (investigational lipid for parenteral nutrition), Intralipid® 20%; Drug
Lead sponsor: Fresenius Kabi; Industry
Eligibility: 0 Weeks and older
Enrollment: 204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 13
States / cities: Palo Alto, California • San Diego, California • New Haven, Connecticut + 8 more

Conditions: Diabetic Retinopathy
Interventions: Online Survey; Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 1,811 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Diabetes, Gestational, Gestational Weight Gain, Postpartum Weight Retention
Interventions: Medically Tailored Meals; Behavioral
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older · Female only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Asthma
Interventions: GW685698X; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 627 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 94
States / cities: Phoenix, Arizona • Fort Smith, Arkansas • Little Rock, Arkansas + 82 more

Conditions: Reversible Pulpitis, Caries
Interventions: Formocresol application after pulpotomy preparation, GENTLEray 980 Soft Tissue diode laser; Procedure
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 3 Years to 8 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Non-alcoholic Steatohepatitis
Interventions: Placebo, BFKB8488A; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 39
States / cities: Cullman, Alabama • Chandler, Arizona • Tucson, Arizona + 30 more

Conditions: Temporomandibular Joint and Muscle Disorder
Interventions: Biobehavioral, Active Coping/Attention Intervention; Behavioral
Lead sponsor: The University of Texas at Arlington; Other
Eligibility: 18 Years and older
Enrollment: 456 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Arlington, Texas

Conditions: Type 1 Diabetes Mellitus
Interventions: Insulin Aspart versus Insulin Lispro, Insulin Lispro versus Insulin Aspart; Drug
Lead sponsor: Joslin Diabetes Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy Subject
Interventions: Behavioral Dietary Intervention, Educational Intervention, Exercise Intervention, Laboratory Biomarker Analysis, Questionnaire Administration; Behavioral · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2027
U.S. locations: 1
States / cities: Duarte, California

Conditions: Wounds and Injuries
Interventions: Embolization; Procedure
Lead sponsor: Oslo University Hospital; Other
Eligibility: 16 Years to 80 Years
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 3
States / cities: Denver, Colorado • Pittsburgh, Pennsylvania • Seattle, Washington

Conditions: Childhood Cancer
Interventions: Attention Training, Placebo; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 8 Years to 16 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Patients With Peripheral Intravenous Access Lines
Interventions: Ultrasound-guided peripheral intravenous access line placement, Landmark Approach to peripheral intravenous access line placement; Procedure
Lead sponsor: George Washington University; Other
Eligibility: 18 Years and older
Enrollment: 1,189 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Sleep Disturbance, Autism Spectrum Disorder
Interventions: Modified Sleep and Circadian Intervention, Enhanced Usual Care; Behavioral
Lead sponsor: Case Western Reserve University; Other
Eligibility: 6 Years to 12 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Cystic Fibrosis, Non-CF Bronchiectasis
Interventions: Xenon; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 5 Years to 100 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: Cincinnati, Ohio

Search by objective public record fields.

Bilateral Transversus Abdominis Plane Block With Exparel Verus Continuous Epidural Analgesia With Bupivacaine

Study of Efficacy and Safety of Brodalumab Compared With Placebo in Subjects With Axial Spondyloarthritis

A Study to Evaluate the Efficacy, Safety, and Tolerability of Tapentadol ER Compared With Placebo in Patients With Chronic, Painful Diabetic Peripheral Neuropathy

A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor

Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo

Activity Based Locomotor Exercise PrOgram-Wait-list controllEd Research

Evaluation of a New EUS-guided Needle (ProCore) Comparing to EUS-TCB Needle (Quick-Core)

A Trial of Tolerogenic Immunosuppression in Highly Sensitized Renal Transplant Recipients

Comparison of the Efficacy & Safety of Resusix With FP24 in Patients With Acquired Coagulopathy

A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

Phase 3 Study to Compare Safety and Efficacy of Smoflipid 20% to Intralipid 20% in Hospitalized Neonates and Infants

Video-based Patient Education Intervention for Diabetic Eye Screening in Latinx Communities

Meals for Moms: Medically-Tailored Meals for Women Who Had Gestational Diabetes

A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Asthma Uncontrolled on Moderate-Dose ICS Therapy.

Electrical and Formocresol Pulpotomy in Primary Molars

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BFKB8488A Compared With Placebo in Participants With Non-Alcoholic Steatohepatitis

An Implementation and Biobehavioral Study of Temporomandibular Joint and Muscle Disorder (TMJMD)

Glycemic Stability of Insulin Aspart Versus Insulin Lispro in Insulin Pump Therapy

Eat, Move, Live Intervention in Reducing Chronic Disease Risk in Medically Vulnerable Communities

Splenic Injury Embolization - the Question About NOM (SInE Qua NOM)

Inattention in Childhood Cancer Survivors

Evaluate Initial Success Rate of Ultrasound Guided Versus Landmark Approach For Peripheral Intravenous Access

Community-Engaged Sleep Intervention for School-Aged Children With Autism Spectrum Disorder

Regional Phenotyping of CF and Non-CF Bronchiectasis